COMP <GO>
DXCM vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
DexCom Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: DXCM 8
— ABBV 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $82.29 (+2.95%) • MKT CAP: $30.16B
roic
21.60%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DXCM VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DXCM | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.10% | 70.20% | -10.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 21.60% | 29.00% | -7.40 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.2x | 33.3x | -8.10 | DXCM | /valuation <GO> |
| Free Cash Flow Yield | 3.57% | 3.47% | +0.10 | DXCM | /fcf-yield <GO> |
| Operating Margin | 19.60% | 24.60% | -5.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 17.90% | 6.90% | +11.00 | DXCM | /net-margins <GO> |
| Revenue Growth (YoY) | 15.60% | 8.60% | +7.00 | DXCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.14 | 5.33 | +1.81 | DXCM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | DXCM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | DXCM | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 72.8 | -25.03 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.15 | -0.05 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.3x | 113.1x | -82.80 | DXCM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $30.16B | $513.86B | -$483.70B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DXCM REV | ABBV REV | DXCM GROSS % | ABBV GROSS % | DXCM FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.66B | $61.16B | 60.1% | 70.2% | $1.08B | $17.82B |
| FY 2024 | $4.03B | $56.33B | 60.5% | 70.0% | $630.7M | $17.83B |
| FY 2023 | $3.62B | $54.32B | 44.0% | 44.0% | $585.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DXCM // BETA 1.10
ABBV // BETA 1.15